Cantor Fitzgerald’s Evolent Health EVH Stock Holding History

Cantor Fitzgerald’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,757	Closed	-$252K	–	595
2023 Q1	$252K	Sell	7,757 -217	-3%	-$6.86K	0.01%	516
2022 Q4	$224K	Buy	7,974 +57	+0.7%	+$1.63K	﹤0.01%	558
2022 Q3	$284K	Buy	+7,917	New	+$279K	0.01%	573

Other funds holding EVH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Cantor Fitzgerald's EVH Position: Q2 2023 in Review

Cantor Fitzgerald sold out of Evolent Health (EVH) in Q2 2023, closing a stake of 7,757 shares — an estimated $252K sold.

Cantor Fitzgerald first reported a position in EVH in Q3 2022 and held it in 3 quarters. The position peaked at $284K in Q3 2022. 217 funds tracked by Wall St. Rank hold EVH as of Q2 2023.

Cantor Fitzgerald reported no remaining Evolent Health position as of Q2 2023 after selling out during the quarter.
Cantor Fitzgerald sold 7,757 Evolent Health shares in Q2 2023, an estimated $252K.
Cantor Fitzgerald first reported a position in Evolent Health in Q3 2022 and held it in 3 quarters.
Cantor Fitzgerald's Evolent Health position peaked at $284K in Q3 2022.
217 funds tracked by Wall St. Rank held Evolent Health as of Q2 2023.

Based on Cantor Fitzgerald's 13F filing for Q2 2023, filed 14 Aug 2023.